CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) (“Enumeral” or the “Company”), a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today reported financial results for the quarter ended June 30, 2015. “We are pleased with the recent progress we have made in our pipeline, especially with our PD-1 and TIM-3 antibody programs,” said Arthur H. Tinkelenberg, Ph.D.,
| < Prev | Next > |
|---|
